Novo Nordisk's oral Wegovy is attracting new patients who were previously unwilling to undergo injection therapy, while Eli Lilly is preparing to launch an oral version to compete. Early demand suggests the category is achieving growth beyond the natural conversion of existing patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.